Sheiner Lecture Series | Encore Lecture and Table Talk with Stephen Duffull
Recorded On: 09/18/2024
-
You must log in to register
- Member - Free!
This Sheiner Lecture Series revisits each of the Lewis B. Sheiner Award winner's exceptional lectures, counting back from the very first one in 2008. Each month, the series will highlight a previous award winner with two sessions: Part 1 will be a 20-minute "Table Talk" to get to know the award winners; Part 2 will be an encore presentation of the award-winning lectures.
Marc R. Gastonguay
Dr. Marc Gastonguay has dedicated more than 30 years to science, advocacy, innovation, and education in the discipline of pharmacometrics. He is the co-founder and former CEO of Metrum Research Group, a provider of strategic biomedical modeling and simulation solutions. He currently serves the company as Entrepreneur in Residence and Chairman of the Board. Dr. Gastonguay received a BS in Pharmacy from the University of Connecticut, a PhD in Pharmacology from Georgetown University School of Medicine, and completed a Postdoctoral Fellowship at the US Food and Drug Administration. Through graduate faculty and adjunct faculty appointments, Dr. Gastonguay has advised more than 20 doctoral students and fellows in collaboration with faculty at multiple major research institutions in the U.S. Dr. Gastonguay is a founding Director and Fellow of the International Society of Pharmacometrics (ISoP), and a member of the American Society of Clinical Pharmacology and Therapeutics. Other recognitions include the ASCPT Sheiner-Beal Pharmacometrics Award, the ACCP/Bristol Myers Squibb Mentorship in Clinical Pharmacology Award, the ISoP Lewis B. Sheiner Lecturer Award, the University of Connecticut Distinguished Alumnus Award, the ISoP Innovation Award, and the Marcum CT Tech Top 40 Award (for MetrumRG). Dr. Gastonguay has published more than 75 manuscripts and 150 abstracts. His current research interests include Bayesian modeling methods, quantitative decision-making, pediatric clinical pharmacology, and rare disease drug development. He is also a strong advocate and contributor to open-science initiatives, including open-source software, open disease models and data, and open courseware.